|
|
News Breaks | | | | October 24, 2012 | | 07:48 EDT |  | DSCO | Discovery Labs secures hospital formulary acceptance for Surfaxin
Discovery Labs has initiated commercial launch activities for both products by training and deploying its newly-formed commercial and medical affairs organizations with the goal of securing hospital formulary acceptance for Surfaxin, expected to be commercially available in 2Q13, and adoption of Afectair with an anticipated product availability in December 2012. | |
|
News For DSCO From The Last 14 Days Check below for free stories on DSCO the last two weeks. |
|
|
| June 10, 2013 | | 07:46 EDT | | DSCO | Discovery Labs responds to FDA request for clarification of submitted Surfaxin
Discovery Laboratories announced that it submitted a response to the FDA recent correspondence relating to Discovery Labs' recently updated product specifications for SURFAXIN. Discovery Labs expects that the FDA may take up to four months to review the information provided. If its plan is successful and the FDA agrees with the response, Discovery Labs expects to proceed with the commercial introduction of SURFAXIN in the fourth quarter of 2013. | |
|
|
|
|
|
|
